# A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

> **NCT05875727** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 405 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** 20-valent pneumococcal conjugate vaccine

## Key facts

- **NCT ID:** NCT05875727
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-16
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05875727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05875727, "A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05875727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*